Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andrea Mayer-Mokler"'
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Harpreet Singh, Jason Luke, Mamta Kalra, Martin Wermke, Dejka Araujo, Ali Mohamed, Winfried Alsdorf, Apostolia-Maria Tsimberidou, Andrea Mayer-Mokler, Arun Satelli, Carsten Reinhardt, Dominik Maurer, George Jr Blumenschein, Kerstin Guenther, Manik Chatterjee, Norbert Hilf, Regina Mendrzyk, Steffen Walter, Stephen Eck, Tobias AW Holderried, Toni Weinschenk, Van Morris, Cedrik M Britten
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/bc94a9e9c64e462b8ba5414a6783526f
Autor:
Luigi Buonaguro, Hans-Georg Rammensee, Harpreet Singh-Jasuja, Roberto S. Accolla, Toni Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Mercedes Iñarrairaegui, Roberta Penta, Caterina Fusco, Maria Tagliamonte, Greta Forlani, Cécile Gouttefangeas, Regina Heidenreich, Tanguy Chaumette, Danila Valmori, Marco Borrelli, Heiko Schuster, Regina Mendrzyk, Katrin Aslan, Christian Flohr, Diego Duarte Alcoba, Jörg Ludwig, Antonio Avallone, Alessandro Inno, Luisa Vonghia, Sven Francque, Bruno Sangro, Yuk Ting Ma, Alfred Königsrainer, Paolo A. Ascierto, Andrea Mayer-Mokler, Francesco Izzo, Stefania Gori, Markus W. Löffler
Purpose:Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72da2ecb08d0ce79371835731a463971
https://doi.org/10.1158/1078-0432.c.6532524.v1
https://doi.org/10.1158/1078-0432.c.6532524.v1
Autor:
Luigi Buonaguro, Hans-Georg Rammensee, Harpreet Singh-Jasuja, Roberto S. Accolla, Toni Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Mercedes Iñarrairaegui, Roberta Penta, Caterina Fusco, Maria Tagliamonte, Greta Forlani, Cécile Gouttefangeas, Regina Heidenreich, Tanguy Chaumette, Danila Valmori, Marco Borrelli, Heiko Schuster, Regina Mendrzyk, Katrin Aslan, Christian Flohr, Diego Duarte Alcoba, Jörg Ludwig, Antonio Avallone, Alessandro Inno, Luisa Vonghia, Sven Francque, Bruno Sangro, Yuk Ting Ma, Alfred Königsrainer, Paolo A. Ascierto, Andrea Mayer-Mokler, Francesco Izzo, Stefania Gori, Markus W. Löffler
Supplementary Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974db9314e1841dc5d5fb343fce288cc
https://doi.org/10.1158/1078-0432.22487466.v1
https://doi.org/10.1158/1078-0432.22487466.v1
Autor:
Markus W. Löffler, Stefania Gori, Francesco Izzo, Andrea Mayer-Mokler, Paolo A. Ascierto, Alfred Königsrainer, Yuk Ting Ma, Bruno Sangro, Sven Francque, Luisa Vonghia, Alessandro Inno, Antonio Avallone, Jörg Ludwig, Diego Duarte Alcoba, Christian Flohr, Katrin Aslan, Regina Mendrzyk, Heiko Schuster, Marco Borrelli, Danila Valmori, Tanguy Chaumette, Regina Heidenreich, Cécile Gouttefangeas, Greta Forlani, Maria Tagliamonte, Caterina Fusco, Roberta Penta, Mercedes Iñarrairaegui, Ulrike Gnad-Vogt, Carsten Reinhardt, Toni Weinschenk, Roberto S. Accolla, Harpreet Singh-Jasuja, Hans-Georg Rammensee, Luigi Buonaguro
Publikováno v:
Clinical cancer research
Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines mu
Autor:
Cedrik M. Britten, Regina Mendrzyk, Manik Chatterjee, Tobias A. W. Holderried, Norbert Hilf, Van K. Morris, Andrea Mayer-Mokler, Dominik Maurer, Jason J. Luke, Martin Wermke, Kerstin Guenther, Carsten Reinhardt, Stephen Eck, Dejka M. Araujo, Mamta Kalra, Harpreet Singh, Toni Weinschenk, George Jr Blumenschein, Ali Mohamed, Arun Satelli, Apostolia-Maria Tsimberidou, Winfried Alsdorf, Steffen Walter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapy demonstrated significant clinical benefit in patients with hematological malignancies but results in most solid tumors have been less encouraging so far.In the IMA203 trial we are treating advanced solid cancer patient
Autor:
Luigi Buonaguro, Andrea Mayer-Mokler, Christian Flohr, Carsten Reinhardt, Harpreet Singh-Jasuja, Roberto Accolla, Giovanna Tosi, Yuk T. Ma, David Adams, Danila Valmori, Regina Heidenreich, Ulrike Gnad-Vogt, Alfred Königsrainer, Markus Löffler, Hans-Georg Rammensee, Bruno Sangro, Sven Francque, Maria Tagliamonte, Annacarmen Petrizzo, Maria Lina Tornesello, Franco M. Buonaguro
Publikováno v:
Cytokine & Growth Factor Reviews. 46:66
Autor:
Joerg Ludwig, Regina Heidenreich, Hans-Georg Rammensee, Markus W. Loeffler, Toni Weinschenk, Roberto S. Accolla, Sven Francque, Yuk Ting Ma, Tanguy Chaumette, Andrea Mayer-Mokler, Senta Ulrike Gnad-Vogt, Luigi Buonaguro, Ester Simeone, Christian Flohr, Carsten Reinhardt, Alfred Koenigsrainer, Mercedes Iñarrairaegui, Cécile Gouttefangeas, Harpreet Singh, Antonio Avallone
Publikováno v:
Journal of Clinical Oncology. 36:TPS3135-TPS3135
TPS3135Background: HCC is the third leading cause of death from cancer globally with an extremely variable 5-year survival rate. The HepaVac-101 phase I/II, first-in-man, therapeutic cancer vaccine...
Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b8054b9c57112fe963edeac55bb124
https://europepmc.org/articles/PMC4514142/
https://europepmc.org/articles/PMC4514142/
Autor:
Toni Weinschenk, Sven Francque, Danila Valmori, Regina Heidenreich, Sarah Kutscher, Hans-Georg Rammensee, Francesco Izzo, Bruno Sangro, Luigi Buonaguro, Carsten Reinhardt, Yuk Ting Ma, Roberto S. Accolla, Alfred Koenigsrainer, Markus W. Loeffler, Ulrike Gnad-Vogt, Christian Flohr, Phillip Mueller, Harpreet Singh, Andrea Mayer-Mokler
Publikováno v:
Cancer Immunology Research. 4:A043-A043
Hepatocellular (HCC)/normal adjacent tissue matched samples have been collected for HLA immunopeptidome analysis. 17 HCC samples from HLA-A*02+ patients and 15 samples from HLA-A*24+ patients have been analysed by mass spectrometry (LC-MS/MS). RNA-ex